Abuse Liability of Hydrocodone Combination Products

Published Online: Tuesday, January 21, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.
 
This is the sixth in a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
A drug therapy for epilepsy and shingles pain is being voluntarily recalled by its manufacturer due to complaints of empty capsules.
A former pharmacy technician thought the prescription pill records she was finagling were better shred than read.
A Maryland pharmacist has been charged with the theft of more than 7300 tablets of hydrocodone, a painkiller found in Vicodin and Lortab.
Latest Issues
$auto_registration$